Aryl oximes

US7135471B2 · kind B2 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Hans-Michael Eggenweiler · Darmstadt, DE
• Norbert Beier · Reinheim, DE
• Pierre Schelling · Mühltal, DE
• Michael Wolf · Darmstadt, DE

Key dates

• Filing date: May 16, 2003
• Grant date: Nov 14, 2006
• Expiry date: May 17, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D403/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Aryl oxime derivatives of the formula (I), in which R1, R2, R3, X and B are as defined in claim 1, act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS